Systematic review of the use of translated patient-reported outcome measures in cancer trials

被引：0
作者：
A. L. Slade
A. Retzer
K. Ahmed
D. Kyte
T. Keeley
J. Armes
J. M. Brown
L. Calman
A. Gavin
A. W. Glaser
D. M. Greenfield
A. Lanceley
R. M. Taylor
G. Velikova
G. Turner
M. J. Calvert
机构：
[1] University of Birmingham,Centre for Patient Reported Outcomes Research, Institute of Applied Health Research
[2] University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham,National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre
[3] University of Birmingham,National Institute for Health Research Surgical Reconstruction and Microbiology Research Centre
[4] University of Birmingham,Birmingham Clinical Trials Unit
[5] National Cancer Research Institute (NCRI) Psychosocial Oncology and Survivorship Clinical Studies Group subgroup: Understanding and measuring the consequences of cancer and its treatment,Patient Centred Outcomes
[6] GlaxoSmithKline,School of Health Sciences
[7] University of Surrey,Clinical Trials Research Unit
[8] NIHR Applied Research Collaboration Kent Surrey & Sussex University of Surrey,Macmillan Survivorship Research Group, Health Sciences
[9] University of Leeds,Northern Ireland Cancer Registry, Centre for Public Health
[10] University of Southampton,Leeds Institute of Medical Research at St James’s
[11] Queens University Belfast,Elizabeth Garrett Anderson Institute for Women’s Health
[12] University of Leeds,Cancer Clinical Trials Unit
[13] Sheffield Teaching Hospital NHS Foundation Trust,National Institute for Health Research Applied Research Collaboration
[14] University College London,Birmingham Health Partners Centre for Regulatory Science and Innovation
[15] University College London Hospitals NHS Foundation Trust,undefined
[16] University of Birmingham,undefined
[17] University of Birmingham,undefined
来源：
Trials | / 22卷
关键词：
Patient-reported outcomes (PROs), Patient-reported outcome measures (PROMs), Ethnicity, Recruitment, Cross-cultural translation, Clinical trials, Trial protocols, Primary outcomes, Secondary outcomes;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 393 条
  • [21] Kris MG(2016)PICASSO III: a phase III, placebo-controlled study of doxorubicin with or without palifosfamide in patients with metastatic soft tissue sarcoma J Clin Oncol 34 642-418
  • [22] Scher HI(2012)Trastuzumab emtansine for HER2-positive advanced breast cancer N Engl J Med 367 1412-4476
  • [23] Schrag D(2014)Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2–positive locally advanced or metastatic breast cancer Cancer. 120 150-25
  • [24] Weldring T(2014)Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study J Clin Oncol 32 402-13
  • [25] Smith SMS(2016)Comparing hospital and telephone follow-up for patients treated for stage–I endometrial cancer (ENDCAT trial): a randomised, multicentre, non-inferiority trial BJOG Int J Obstet Gynaecol 124 4470-494
  • [26] Calvert M(2015)Development and evaluation of a specifically designed website for haematopoietic stem cell transplant patients in Leeds Eur J Cancer Care 25 12-602
  • [27] Blazeby J(2012)Acupuncture for cancer-related fatigue in patients with breast cancer: a pragmatic randomized controlled trial J Clin Oncol 30 3-e52
  • [28] Altman DG(2014)The effectiveness of acupressure for the control and management of chemotherapy-related acute and delayed nausea: a randomized controlled trial J Pain Symptom Manag 47 3-326
  • [29] Revicki DA(2014)Patient-reported measurement of time to diagnosis in cancer: development of the Cancer Symptom Interval Measure (C-SIM) and randomised controlled trial of method of delivery BMC Health Serv Res 14 483-48
  • [30] Moher D(2011)Advance care planning in advanced cancer: can it be achieved? An exploratory randomized patient preference trial of a care planning discussion Palliat Support Care 9 596-1177
12345678910